Hormonal
GLP-1 receptor agonists (Liraglutide and Semaglutide) promote weight loss and modulate gut microbiota towards a lean-related profile, although clinical data on their specific impact on gut microbiota composition is currently limited.
GLP-1 agonists like Liraglutide and Semaglutide are effective pharmacological treatments for obesity, producing significant weight loss (approx. 6-8%) when combined with lifestyle changes. While they show promise in improving gut microbiota in animal studies, clinical data on these specific changes is still emerging.
Liraglutide and semaglutide, both GLP-1 receptor (GLP-1R) agonists, are widely used in obesity pharmacotherapy... promoting weight loss through appetite suppression... preclinical studies have demonstrated that semaglutide effectively improved high-fat diet induced dysbiosis... liraglutide administration seems to enhance gut microbiota diversity and richness... there is currently no published clinical data regarding the effect of semaglutide administration on gut microbiota.
Why this rating
Strong clinical evidence for weight loss, but weak/limited clinical evidence for specific microbiota changes.
Source
The Gut–Brain Axis in Obesity: Mechanisms, Development, and Therapeutic Perspectives
Laura Arellano-García et al. · Current Nutrition Reports · 2026
DOI 10.1007/s13668-026-00732-w
More from this paper
- Caloric restriction interventions restore gut-brain axis communication in obesity by enriching beneficial bacteria (e.g., Akkermansia muciniphila), reducing LPS-mediated endotoxemia, and modulating SCFA production to enhance satiety signaling.Good
- Obesity is associated with gut microbiota dysbiosis characterized by reduced diversity, altered taxonomic abundance, and impaired gut-brain axis communication, leading to dysregulated appetite and energy homeostasis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →